Company profile: Asterias Biotherapeutics
1.1 - Company Overview
Company description
- Provider of regenerative medicine therapeutic product development targeting neurology, oncology, cardiology, metabolic diseases, ophthalmology, orthopedics, and blood and vascular diseases, including human embryonic stem cell development.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Asterias Biotherapeutics
Ensoma
HQ: United States
Website
- Description: Provider of one-time in vivo genomic medicine solutions, including the Engenious platform for multi-cellular genome editing to engineer hematopoietic and immune cells via a single outpatient treatment; virus-like particle delivery systems devoid of viral genes with up to 35 kb payloads to minimize immune responses; smart cell therapies for cancer; and integrated tools for gene replacement, editing, endogenous protein therapies, and regulatory elements.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ensoma company profile →
International Stem Cell
HQ: United States
Website
- Description: Provider of parthenogenesis-based stem cell technologies, including ISC-hpNSC neural stem cells for Parkinson’s disease; Lifeline Cell Technology human cell culture products; Lifeline Skin Care cosmetics using pluripotent stem cell extracts; ChondroStem cartilage regeneration using 3D bioprinting for osteoarthritis; CytoHep hepatocyte-like cells for liver diseases; and Parkinson’s clinical trials in Australia via Cyto Therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full International Stem Cell company profile →
BlueRock Therapeutics
HQ: Canada
Website
- Description: Provider of induced pluripotent stem cell (iPSC) therapies using an industry-leading platform, with programs including bemdaneprocel for Parkinson’s disease, OpCT-001 for primary photoreceptor diseases to restore vision, BR-CM01 to replace damaged heart cells after myocardial infarction or heart failure, and pre-clinical Treg-based therapies for autoimmune disorders; conducts clinical trials to assess safety and efficacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BlueRock Therapeutics company profile →
Zelluna
HQ: Norway
Website
- Description: Provider of TCR-based immunotherapies, developing off-the-shelf TCR-guided NK cell therapies for solid tumors. Pipeline includes a MAGE-A4 TCR-NK therapy for cancer advancing toward clinical trials, leveraging a wide range of TCRs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zelluna company profile →
Coapt Systems
HQ: United States
Website
- Description: Provider of bio-absorbable implants for soft tissue fixation during facial cosmetic surgery, engaged in the design, development, manufacture, and marketing of these devices. Offerings include the ENDOTINE Forehead 3.0 bioabsorbable brow fixation device and ENDOTINE Forehead Instrument Kits comprising insertion tools, drill bits, and sterilization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Coapt Systems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Asterias Biotherapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Asterias Biotherapeutics
2.2 - Growth funds investing in similar companies to Asterias Biotherapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Asterias Biotherapeutics
4.2 - Public trading comparable groups for Asterias Biotherapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →